---
title: "NAD Precursors Billing & Prior-Auth Playbook | HealthRX.com"
description: "This practical guide covers billing codes, prior-authorization strategies, and prescribing essentials for NAD precursors including NMN, NR, and IV NAD+."
url: https://healthrx.com/classes-nad-precursors/billing-and-prior-auth
publisher: HealthRX.com
---


HealthRX.com

No NAD+ precursor is FDA-approved, so none is billable as a drug

[Print or save as PDF](https://healthrx.com/printables/classes-nad-precursors/billing-and-prior-auth?print=1)

Key numbers

- 250 mg/day Oral NMN dose in a 12-week randomized trial of 30 healthy adults, where blood NAD+ rose Source: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35479740/), as cited Oct 30, 2026
- 300 to 900 mg/day Oral NMN dose range in a 60-day randomized trial of 80 middle-aged adults, where blood NAD+ rose Source: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36482258/), as cited Oct 30, 2026
- 2,000 mg/day Studied oral NR dose over 12 weeks; a research dose, not a recommended dose Source: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29992272/), as cited Oct 30, 2026

HealthRX.com quick answer. No NAD+ precursor is an FDA-approved drug, so none has an approved label or labeled indication: NMN and NR are sold as oral dietary supplements, and injectable NAD+ is a compounded product [1][2]. FDA's status information does not address billing codes, payer coverage or prior authorization, so none of that is established here.

At a glance

- What is sold / Oral NMN and NR as supplements; injectable NAD+ as a compounded product [1][2]
- Approval status / No NAD+-precursor product is approved to treat aging or any disease [1]
- NMN today / Lawful in dietary supplements after FDA's September 2025 reversal; new-dietary-ingredient rules still apply [1]
- NR / Sold as a supplement; FDA had no questions on one company's GRAS notice in 2016 and made no GRAS finding of its own [3]
- Human data / Blood NAD+ rises with oral NMN and NR in randomized trials; clinical benefit is uncertain [4][5][6]

## Is any NAD+ precursor an FDA-approved drug?

No. No NAD+-precursor product is approved by FDA to treat aging or any disease [1], and injectable or IV NAD+ is a compounded product, not an approved drug [2]. There is no approved label or labeled indication in this class.

Questions worth asking

Choose the questions you want to keep Is my prescriber billing this as an approved drug, or as a supplement or compounded product? Does my insurance plan cover any NAD+ precursor, and does it need a prior authorization? If I take an NMN or NR supplement, will it be billed to my insurance at all? Is the IV NAD+ infusion you are offering a compounded product, and where is the compounding pharmacy licensed? Can you give me a written reason for the prior authorization request, and which payer criteria does it meet? Which human trial results would you point to as the basis for prescribing NAD+ precursors to me?

## What is the FDA status of NMN, NR and injectable NAD+?

### NMN

Trade press reported that in 2022 FDA told two ingredient makers that NMN was excluded from the supplement definition under the drug-exclusion clause. The Natural Products Association and the Alliance for Natural Health USA filed a citizen petition in March 2023 (docket FDA-2023-P-0872), and FDA sent an interim no-decision response on 30 August 2023 [7]. On 29 September 2025 FDA posted a partial approval and denial response concluding that NMN is not excluded, because it found evidence NMN was sold as a supplement in the US before it was authorized for drug investigation [1]. Before selling NMN, a maker must file a new-dietary-ingredient notification or rely on a prior notification covering its ingredient [1]. NMN is still not an FDA-approved drug [1].

### NR

FDA answered ChromaDex's GRAS notice GRN 000635 with a no-questions letter dated 3 August 2016 and stated that it had not made its own GRAS determination [3]. NR is sold as a dietary supplement [1].

### Injectable NAD+

Injectable or IV NAD+ is a compounded product and is not an FDA-approved drug [2]. Injectable [NAD+](https://healthrx.com/products/nad-injection) sits in a different category from oral NMN and NR, which reach the market as dietary supplements rather than as drugs.

## What human trials have found

Blood NAD+ rises with oral NMN and NR in randomized trials: NMN 250 mg/day for 12 weeks in 30 healthy adults [4], NMN 300 to 900 mg/day for 60 days in 80 middle-aged adults [5], and a six-week randomized crossover trial in which NR increased NAD+ metabolism in middle-aged and older adults [6]. One 10-week trial in postmenopausal women with [prediabetes](https://healthrx.com/conditions-prediabetes/diagnosis-algorithm) found NMN improved insulin-stimulated glucose disposal [8]. Broader clinical benefit remains uncertain: in a 21-day trial of 12 older men, NR did not raise muscle NAD+ although a marker of NAD+ synthesis doubled, and mitochondrial respiration was unchanged [9]; a 2025 meta-analysis found NMN had no significant effect on skeletal muscle index, handgrip strength, gait speed or the chair-stand test in older adults [10]; and a 2025 meta-analysis of 12 studies and 513 participants found most metabolic outcomes did not differ from control [11].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the article, how is injectable or IV NAD+ classified?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Printable coverage checklist

NAD precursor billing and prior authorization checklist

Use this sheet before a visit, call or claim involving NMN, NR or injectable NAD+. It helps you record the product, gather proof of its status and track what the insurer or pharmacy says about coverage.

[Open the fill-in sheet](https://healthrx.com/printables/classes-nad-precursors/billing-and-prior-auth) Fill it in, print it or save it as a PDF. No sign-up.

Frequently asked questions

Will insurance pay for an IV NAD+ infusion?

FDA's status information does not establish coverage. Injectable NAD+ is compounded and is not an FDA-approved drug [2].

Is NMN still excluded from the supplement definition?

No. FDA responded to the citizen petition on 29 September 2025 and concluded NMN is not excluded [1]. Before selling it, a maker must file a new-dietary-ingredient notification or rely on a prior notification covering its ingredient [1].

What doses were used in the human trials?

NMN: 250 mg/day for 12 weeks [4], 300 to 900 mg/day for 60 days [5], and 1,250 mg once daily for up to 4 weeks [12]. NR: 2,000 mg/day for 12 weeks [13] and 3,000 mg/day for 4 weeks in Parkinson disease [14]. These are studied doses, not recommended doses.

References

Show all 14 references Hide references

1. [Official web page](https://www.regulations.gov/document/FDA-2023-P-0872-2754).
2. [Bulk Drug Substances Used in Compounding of the FD&C Act | FDA](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act).
3. [Agency Response Letter GRAS Notice No. GRN 000635 | FDA](https://www.fda.gov/food/gras-notice-inventory/agency-response-letter-gras-notice-no-grn-000635).
4. Okabe K, Yaku K, Uchida Y, Fukamizu Y, Sato T, Sakurai T, et al. [Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects](https://pubmed.ncbi.nlm.nih.gov/35479740/). Front Nutr. 2022;9:868640.
5. Yi L, Maier AB, Tao R, Lin Z, Vaidya A, Pendse S, et al. [The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial](https://pubmed.ncbi.nlm.nih.gov/36482258/). Geroscience. 2023;45(1):29-43.
6. Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, et al. [Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults](https://pubmed.ncbi.nlm.nih.gov/29599478/). Nat Commun. 2018;9(1):1286.
7. [Official web page](https://www.regulations.gov/docket/FDA-2023-P-0872).
8. Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, et al. [Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women](https://pubmed.ncbi.nlm.nih.gov/33888596/). Science. 2021;372(6547):1224-1229.
9. Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, et al. [Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures](https://pubmed.ncbi.nlm.nih.gov/31412242/). Cell Rep. 2019;28(7):1717-1728.e6.
10. Prokopidis K, Moriarty F, Bahat G, McLean J, Church DD, Patel HP. [The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/40275690/). J Cachexia Sarcopenia Muscle. 2025;16(3):e13799.
11. Zhang J, Poon ET, Wong SH. [Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/39116016/). Crit Rev Food Sci Nutr. 2025;65(22):4382-4400.
12. Fukamizu Y, Uchida Y, Shigekawa A, Sato T, Kosaka H, Sakurai T. [Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women](https://pubmed.ncbi.nlm.nih.gov/36002548/). Sci Rep. 2022;12(1):14442.
13. Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, et al. [A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects](https://pubmed.ncbi.nlm.nih.gov/29992272/). Am J Clin Nutr. 2018;108(2):343-353.
14. Berven H, Kverneng S, Sheard E, Søgnen M, Af Geijerstam SA, Haugarvoll K, et al. [NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/38016950/). Nat Commun. 2023;14(1):7793.

Next in this cluster

Related reading

- [nad precursors NAD precursors adverse events](https://healthrx.com/classes-nad-precursors/adverse-event-management)
- [nad precursors NAD precursors](https://healthrx.com/classes-nad-precursors/class-overview-monograph)
- [nad precursors NAD precursors monitoring bundle](https://healthrx.com/classes-nad-precursors/monitoring-bundle)
- [nad precursors NAD Precursors Special-Populations Summary](https://healthrx.com/classes-nad-precursors/special-populations-summary)
- [nad precursors NAD precursors](https://healthrx.com/classes-nad-precursors/titration-tapering-algorithm)
- [nad precursors NAD precursors](https://healthrx.com/classes-nad-precursors/when-to-pick-which)
- [progestins vs synthetic Micronized progesterone](https://healthrx.com/classes-progestins/when-to-pick-which)
- [serms SERMs billing](https://healthrx.com/classes-selective-er-modulators/billing-and-prior-auth)
- [testosterone formulations Testosterone formulations adverse events](https://healthrx.com/classes-testosterone-formulations/adverse-event-management)
- [testosterone formulations Testosterone Formulations Billing & Prior-Auth Playbook](https://healthrx.com/classes-testosterone-formulations/billing-and-prior-auth)

![NAD precursor billing: woman on the phone with paperwork and calculator at a home office desk](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/classes-nad-precursors/billing-and-prior-auth.webp)

Because these supplements are not FDA-approved drugs, coverage questions often mean long phone calls and paperwork rather than routine prior authorization. Full NAD precursors billing guide and sources at [healthrx.com/classes-nad-precursors](https://healthrx.com/classes-nad-precursors).

> Compounded drugs are not FDA-approved or reviewed by FDA for safety, effectiveness, or quality before marketing.
